國家衛生研究院 NHRI:Item 3990099045/12468
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 856849      在线人数 : 939
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/12468


    题名: Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes
    作者: Yen, FS;Yang, YC;Hwu, CM;Wei, JC;Huang, YH;Hou, MC;Hsu, CC
    贡献者: Institute of Population Health Sciences
    摘要: BACKGROUND & AIMS: Studies have described prominent histologic improvement in patients with nonalcoholic steatohepatitis (NASH) using thiazolidinedione (TZD); however, these were all short-term with moderate sample size, no liver-related long-term outcomes could be noted. METHODS: This retrospective cohort study enrolled patients with newly diagnosed type 2 diabetes mellitus (T2DM) from Taiwan's National Health Insurance Research Database between January 1, 2000, and December 31, 2013. We matched TZD users and nonusers at a 1:1 ratio through propensity score matching. This study included 5095 paired TZD users and nonusers. Cox proportional hazard models were used to compare the risks of liver cirrhosis, hepatic decompensation, hepatic failure, and all-cause mortality between TZD users and nonusers. The Kaplan-Meier method was used to compare the cumulative incidence of these main outcomes. RESULTS: The incidence rates of liver cirrhosis, hepatic decompensation, hepatic failure, and all-cause mortality during follow-up were 0.77 versus 1.95, 1.43 versus 1.75, 0.36 versus 0.70, and 4.89 versus 3.78 per 1000 person-years between TZD users and nonusers. The adjusted hazard ratios of liver cirrhosis, hepatic decompensation, hepatic failure, and all-cause mortality were 0.39 (95% confidence interval [CI]: 0.21-0.72), 0.86 (95% CI: 0.52-1.44), 0.46 (95% CI: 0.18-1.17), and 1.18 (95% CI: 0.87-1.61), respectively. CONCLUSIONS: Our study demonstrated that TZD use could significantly lower the risk of liver cirrhosis. In clinical settings, TZD use might be able to improve liver-related long-term outcomes.
    日期: 2020-05
    關聯: Liver International. 2020 May;40(5):1089-1097.
    Link to: http://dx.doi.org/10.1111/liv.14385
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1478-3223&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000512129200001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85079445831
    显示于类别:[許志成] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    PUB31960563.pdf12920KbAdobe PDF317检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈